Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
FOMX was delisted on the 6th of March, 2020.
19 hedge funds and large institutions have $23.7M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2014 Q3 according to their latest regulatory filings, with 19 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$5.87M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$4.31M |
| 3 |
Jennison Associates
New York
|
+$3.59M |
| 4 |
JP Morgan Chase
New York
|
+$3.44M |
| 5 |
DM
Deerfield Management
New York
|
+$2.56M |
Top Sellers
FOMX Hedge Fund Activity: Q3 2014 in Review
19 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q3 2014, worth a combined $23.7M.
Buyers outnumbered sellers: 19 funds opened new FOMX positions and 0 closed out — a net gain of 19 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $5.87M.
- 19 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q3 2014, up from 0 in Q2 2014.
- Funds reported $23.7M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q3 2014.
- 19 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q3 2014 and 0 closed out, a net change of +19 holders.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q3 2014 was Baker Bros. Advisors, an estimated $5.87M added.
Based on aggregated 13F filings for Q3 2014.